Nureca has informed that the Board of Directors of the Company at its meeting held on February 12, 2022, has approved the un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021. Copies of un-audited Financial Results along with Limited Review Reports from the Company's Statutory Auditors are enclosed, declared an Interim Dividend of Rs 3.0 per Equity Share of Rs 10 each at the rate of 30%. The dividend shall be paid/dispatched to the Shareholders on or before 30 days from the date of its declaration, approved the appointment of Sushil Kumar Bhardwaj (DIN 09468448) as an Additional Director & Whole-time Director of the Company designated as Director - Compliance for a period of three years with effect from February 12, 2022, and approved the change of nomenclature of Registered Office Address of the Company from ‘Gala No. 101, 1st Floor, Udyog Bhavan Sonawala Lane, Goregaon East, Mumbai, Maharashtra -400063’ to ‘Office No. 101, 1st Floor, Udyog Bhavan Sonawala Lane, Goregaon East, Mumbai, Maharashtra-400063’ with immediate effect from February 12, 2022. Presentation on financial results for the third quarter and nine months ended December 31, 2021 is also enclosed. The Board Meeting commenced at 7:00 pm and concluded at 9.35 pm.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Poly Medicure | 3162.70 |
Hemant Surgical Inds | 143.00 |
Nureca Ltd. | 298.40 |
Prevest Denpro | 563.05 |
Centenial Surgical | 144.95 |
View more.. |